AstraZeneca PLC (AZN)vsEnliven Therapeutics Inc. (ELVN)
AZN
AstraZeneca PLC
$173.30
-1.13%
HEALTHCARE · Cap: $261.94B
ELVN
Enliven Therapeutics Inc.
$52.97
-1.47%
HEALTHCARE · Cap: $3.80B
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
ELVN
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$173.30
$20.66 discount
Intrinsic value data unavailable for ELVN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : ELVN
The strongest argument for ELVN centers on Debt/Equity, Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : ELVN
The primary concerns for ELVN are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while ELVN is a value play — different risk/reward profiles.
ELVN carries more volatility with a beta of 0.26 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 25/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Enliven Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its proprietary therapeutic platforms. With a robust pipeline of advanced drug candidates developed using cutting-edge biopharmaceutical technologies, the company is dedicated to enhancing patient care and quality of life. Enliven's commitment to scientific excellence and its mission to fulfill unmet needs in oncology strategically position it for substantial shareholder value while making a meaningful contribution to the healthcare ecosystem.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?